Binding Database

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.

Abbott Laboratories

Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.

Boehringer Ingelheim Pharmaceuticals

Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.

Boehringer Ingelheim Pharmaceuticals

Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro.

Harvard Medical School

Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.

Boehringer Ingelheim Pharmaceuticals

Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding.

Exonhit Therapeutics

Testing the substrate-envelope hypothesis with designed pairs of compounds.

Massachusetts Institute Of Technology

Binding of (5S)-penicilloic acid to penicillin binding protein 3.

University Of Oxford

Expanding the Scope of Human DNA Polymerase � and � Inhibitors.

University Of Konstanz

Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor.

Duke University Medical Center

Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.

Georgia Institute Of Technology